Yanina Grant-Huerta - 14 Aug 2026 Form 4 Insider Report for ImageneBio, Inc. (IMA)

Reporting relationship: Chief Financial Officer
Issuer ticker: IMA
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2026, 17:00:11 UTC
Prior SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristin Yarema, Attorney-in-Fact

Key filing fact

Yanina Grant-Huerta filed Form 4 for ImageneBio, Inc. (IMA) on 17 Aug 2026.

Key facts

This page summarizes Yanina Grant-Huerta's Form 4 filing for ImageneBio, Inc. (IMA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2026, 17:00.

Change

Previous filing in this sequence was filed on 28 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002064348 Primary reporting owner

Grant-Huerta Yanina

Relationship: Chief Financial Officer
Address: C/O IMAGENEBIO, INC., 12526 HIGH BLUFF DRIVE, SUITE 345, SAN DIEGO
Signature: /s/ Kristin Yarema, Attorney-in-Fact
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMA transaction

Common Stock

Award

Transaction value
Shares: +65,000
Change %
Price: $0.000000^*
Shares after: 65,000
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1, F2

IMA transaction

Common Stock

Award

Transaction value
Shares: +39,000
Change %: +60%
Price: $0.000000^*
Shares after: 104,000
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +56,000
Change %
Price: $0.000000^*
Shares after: 56,000
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,000
Exercise price: $5.84
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On July 23, 2026, the Issuer filed a Current Report on Form 8-K reporting that the Reporting Person was entitled to receive pursuant to her employment offer letter 65,000 restricted stock units ("RSUs") and 95,000 stock options. It was subsequently determined that in lieu of the foregoing grants which had not yet been made, the Reporting Person would receive 104,000 restricted stock units in the aggregate and 56,000 options (the "Options"). These updated awards were granted on August 14, 2026 and are reported herein.

Footnote F2

Represents the number of shares of the Issuer's Common Stock underlying RSUs. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on July 20, 2027, and the remaining RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.

Footnote F3

The Options vest over four years, with 25% of the shares vesting on July 20, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.